Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HPV16 TCR-engineered T cells CRTE7A2-01

A preparation of T lymphocytes that has been genetically modified to express a T-cell receptor (TCR) specific for an as of yet not identified viral oncoprotein(s) of human papillomavirus type 16 (HPV16), with potential antineoplastic activity. Upon intravenous administration, the anti-HPV16 TCR-engineered T cells CRTE7A2-01 specifically recognize and bind to the HPV16 oncoprotein(s) expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 oncoprotein(s).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-HPV16 TCR T cells CRTE7A2-01 anti-HPV16 TCR-T cells CRTE7A2-01
Code name:	CRTE7A2 01 CRTE7A2-01 CRTE7A201

anti-HPV16 TCR-engineered T cells CRTE7A2-01

Search NCI's Drug Dictionary